Shingrix (zoster vaccine recombinant, adjuvanted) Approved in the U.S. for Prevention of Shingles

London UK 20 October 2017 -- GlaxoSmithKline plc [LSE/NYSE: GSK] today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news